Jefferies Financial Group Inc. Invests $338,000 in MoonLake Immunotherapeutics (NASDAQ:MLTX)

Jefferies Financial Group Inc. purchased a new position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 6,250 shares of the company’s stock, valued at approximately $338,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in MLTX. FMR LLC raised its stake in shares of MoonLake Immunotherapeutics by 28.1% during the 4th quarter. FMR LLC now owns 6,341,391 shares of the company’s stock worth $343,386,000 after purchasing an additional 1,391,167 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of MoonLake Immunotherapeutics by 12.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,343,643 shares of the company’s stock worth $181,059,000 after purchasing an additional 363,394 shares in the last quarter. Federated Hermes Inc. raised its stake in shares of MoonLake Immunotherapeutics by 13.2% during the 4th quarter. Federated Hermes Inc. now owns 1,280,052 shares of the company’s stock worth $69,315,000 after purchasing an additional 149,724 shares in the last quarter. Marshall Wace LLP raised its stake in shares of MoonLake Immunotherapeutics by 7.9% during the 4th quarter. Marshall Wace LLP now owns 1,245,299 shares of the company’s stock worth $67,433,000 after purchasing an additional 90,914 shares in the last quarter. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of MoonLake Immunotherapeutics during the 4th quarter worth about $3,485,000. 93.85% of the stock is owned by hedge funds and other institutional investors.

MoonLake Immunotherapeutics Stock Down 0.1%

Shares of NASDAQ MLTX opened at $37.62 on Friday. The business’s 50 day moving average is $38.40 and its two-hundred day moving average is $44.71. The company has a market cap of $2.41 billion, a P/E ratio of -29.16 and a beta of 1.31. MoonLake Immunotherapeutics has a 12 month low of $31.42 and a 12 month high of $58.26.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.13. During the same period in the prior year, the company earned ($0.22) earnings per share. Sell-side analysts expect that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

MLTX has been the topic of a number of recent analyst reports. Royal Bank of Canada initiated coverage on MoonLake Immunotherapeutics in a research note on Tuesday, March 18th. They issued an “outperform” rating and a $67.00 price objective on the stock. The Goldman Sachs Group cut their price objective on MoonLake Immunotherapeutics from $82.00 to $73.00 and set a “buy” rating on the stock in a research note on Thursday, February 27th. Wedbush reissued an “outperform” rating and issued a $80.00 price objective (up from $78.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 13th. HC Wainwright reissued a “buy” rating and issued a $100.00 price objective on shares of MoonLake Immunotherapeutics in a research note on Thursday, February 27th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $66.00 price objective on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 13th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, MoonLake Immunotherapeutics currently has an average rating of “Moderate Buy” and an average price target of $81.67.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.